174 related articles for article (PubMed ID: 21116878)
1. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
Rozzi A; Salerno M; Bordin F; De Marco F; Di Nicola S; Lanzetta G
Med Oncol; 2011 Dec; 28 Suppl 1():S426-32. PubMed ID: 21116878
[TBL] [Abstract][Full Text] [Related]
2. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma.
Han JJ; Kim YJ; Kim JW; Chang H; Lee JO; Lee KW; Jeong CW; Kim JH; Hong SK; Bang SM; Byun SS; Lee SE; Lee JS
Tumori; 2014; 100(4):439-45. PubMed ID: 25296594
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
Vaishampayan UN; Faulkner JR; Small EJ; Redman BG; Keiser WL; Petrylak DP; Crawford ED
Cancer; 2005 Oct; 104(8):1627-32. PubMed ID: 16138364
[TBL] [Abstract][Full Text] [Related]
8. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
[TBL] [Abstract][Full Text] [Related]
9. A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
Friedland DM; Dakhil S; Hollen C; Gregurich MA; Asmar L
Cancer Invest; 2004; 22(3):374-82. PubMed ID: 15493358
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
Johannsen M; Sachs M; Roigas J; Hinke A; Staack A; Loening SA; Schnorr D; Wille AH
Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
[TBL] [Abstract][Full Text] [Related]
14. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
Small EJ; Lew D; Redman BG; Petrylak DP; Hammond N; Gross HM; Eastham JA; Crawford ED
J Clin Oncol; 2000 Jul; 18(13):2537-44. PubMed ID: 10893284
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Krege S; Rembrink V; Börgermann C; Otto T; Rübben H
J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366
[TBL] [Abstract][Full Text] [Related]
17. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Sep; 14(9):828-32. PubMed ID: 17760750
[TBL] [Abstract][Full Text] [Related]
19. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Bellmunt J; Cos J; Clèries R; Pérez M; Ribas A; Eres N; Murio JE; Margarit C; Baselga J
Cancer Invest; 2002; 20(5-6):673-85. PubMed ID: 12197223
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
Redman BG; Smith DC; Flaherty L; Du W; Hussain M
J Clin Oncol; 1998 May; 16(5):1844-8. PubMed ID: 9586899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]